aminolevulinic acid has been researched along with Diabetes Mellitus, Type 2 in 6 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients." | 2.82 | The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain. ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016) |
| "5-Aminolevulinic acid (5-ALA) is a delta amino acid naturally present in every living cell of the human body." | 2.61 | Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). ( Iftikhar, H; Jabbar, Z; Nakajima, M; Rehani, PR; Rehani, RN; Tanaka, T, 2019) |
| " Thus, in this review, we evaluate the mechanisms of action and adverse effects of common medications used to treat type 2 diabetes mellitus as well as 5-ALA including its mechanism and possible use in diabetes management." | 2.61 | Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). ( Iftikhar, H; Jabbar, Z; Nakajima, M; Rehani, PR; Rehani, RN; Tanaka, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kitamura, N | 1 |
| Zhang, S | 1 |
| Morel, JD | 1 |
| Nagano, U | 1 |
| Taworntawat, T | 1 |
| Hosoda, S | 1 |
| Nakamura, A | 1 |
| Ogawa, Y | 1 |
| Benegiamo, G | 1 |
| Auwerx, J | 1 |
| Tsubota, K | 1 |
| Yokoyama, Y | 1 |
| Watanabe, M | 1 |
| Rehani, PR | 1 |
| Iftikhar, H | 1 |
| Nakajima, M | 2 |
| Tanaka, T | 2 |
| Jabbar, Z | 1 |
| Rehani, RN | 1 |
| Sato, T | 1 |
| Yasuzawa, T | 1 |
| Uesaka, A | 1 |
| Izumi, Y | 1 |
| Kamiya, A | 1 |
| Tsuchiya, K | 1 |
| Kobayashi, Y | 1 |
| Kuwahata, M | 1 |
| Kido, Y | 1 |
| Al-Saber, F | 1 |
| Aldosari, W | 1 |
| Alselaiti, M | 1 |
| Khalfan, H | 1 |
| Kaladari, A | 1 |
| Khan, G | 1 |
| Harb, G | 1 |
| Rehani, R | 1 |
| Kudo, S | 1 |
| Koda, A | 1 |
| Darwish, A | 1 |
| Fai, D | 1 |
| Romano, I | 1 |
| Cassano, N | 1 |
| Vena, GA | 1 |
| Nakamura, Y | 1 |
| Haraguchi, A | 1 |
| Shigeno, R | 1 |
| Ito, A | 1 |
| Horie, I | 1 |
| Kawakami, A | 1 |
| Abiru, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes[NCT02481141] | 53 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in blood glucose levels 2 hours after breakfast (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline | -12.9 |
| 5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline | -8.5 |
| Placebo Through Week 2 Change From Baseline | -26.5 |
| Placebo Through Week 4 Change From Baseline | -18.8 |
| Placebo Through Week 12 Change From Baseline | -33.0 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | kg (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -0.1 |
| 5-ALA-SFC Through Week 12 Change From Baseline | -0.2 |
| Placebo Through Week 6 Change From Baseline | -0.3 |
| Placebo Through Week 12 Change From Baseline | -0.8 |
The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | 2.3 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline | -3.0 |
| Placebo Through Week 2 Change From Baseline | -7.3 |
| Placebo Through Week 4 Change From Baseline | -0.8 |
| Placebo Through Week 12 Change From Baseline | -4.2 |
Change from baseline in HbA1c % (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline | -0.2 |
| 5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline | -0.3 |
| 5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline | -0.7 |
| Placebo Through Week 2 Change From Baseline | -0.5 |
| Placebo Through Week 4 Change From Baseline | -0.5 |
| Placebo Through Week 12 Change From Baseline | -0.5 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -0.8 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 0.5 |
| Placebo Through Week 6 Change From Baseline | -1.6 |
| Placebo Through Week 12 Change From Baseline | -1.1 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -5.2 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 6.8 |
| Placebo Through Week 6 Change From Baseline | -7.6 |
| Placebo Through Week 12 Change From Baseline | -0.1 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -1.3 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 3.2 |
| Placebo Through Week 6 Change From Baseline | 4.5 |
| Placebo Through Week 12 Change From Baseline | 11.9 |
Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12
| Intervention | mg/dL (Mean) |
|---|---|
| 5-ALA-SFC Through Week 6 Change From Baseline | -2.9 |
| 5-ALA-SFC Through Week 12 Change From Baseline | 7.6 |
| Placebo Through Week 6 Change From Baseline | -11.8 |
| Placebo Through Week 12 Change From Baseline | -4.0 |
The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Week 2, Week 4, Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| 5-ALA-SFC Through Week 2 (50 mg 2x/Day) | 6 |
| 5-ALA-SFC Through Week 4 (75 mg 2x/Day) | 8 |
| 5-ALA-SFC Through Week 12 (100 mg 2x/Day) | 2 |
| Placebo Through Week 2 | 3 |
| Placebo Through Week 4 | 1 |
| Placebo Through Week 12 | 1 |
1 review available for aminolevulinic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA).
Topics: Aminolevulinic Acid; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglo | 2019 |
2 trials available for aminolevulinic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
Topics: Abdominal Pain; Aminolevulinic Acid; Bahrain; Blood Glucose; Citric Acid; Cough; Diabetes Mellitus, | 2016 |
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
Topics: Adenosine Triphosphate; Adult; Aminolevulinic Acid; Blood Glucose; Citric Acid; Deafness; Diabetes M | 2021 |
3 other studies available for aminolevulinic acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Sodium ferrous citrate and 5-aminolevulinic acid improve type 2 diabetes by maintaining muscle and mitochondrial health.
Topics: Aminolevulinic Acid; Animals; Citric Acid; Diabetes Mellitus, Type 2; Diet, High-Fat; DNA, Mitochond | 2023 |
Type 2 diabetic conditions in Otsuka Long-Evans Tokushima Fatty rats are ameliorated by 5-aminolevulinic acid.
Topics: Adipocytes; Aminolevulinic Acid; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus | 2014 |
Cutaneous lupus erythematosus of the scalp treated with methyl-aminolevulinate photodynamic therapy: a case report.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Aminolevulinic Acid; Comorbidity; Contraindications; Dia | 2012 |